SELLAS Life Sciences Group, Inc. reported financial results for the quarter ended June 30, 2026, showing a net loss of $9.6 million, or $0.05 per share, compared to a $6.6 million loss in the prior year period. Research and development expenses increased to $6.3 million from $3.9 million, while general and administrative expenses rose to $4.4 million from $3.0 million. The company held $138.3 million in cash as of June 30, 2026. Clinically, the Phase 3 REGAL trial for galinpepimut-S (GPS) is approaching the pre-specified 80th event required for final efficacy analysis, while enrollment continues in the Phase 2 SLS009 study with topline data expected in Q4 2026. The company operates in the biopharmaceutical industry, developing novel cancer therapies.

SELLAS Life Sciences Group, Inc. announced that a sole arbitrator dismissed the company's claims in a binding arbitration against 3D Medicines, Inc. administered by the Hong Kong International Arbitration Centre. The company is required to pay approximately $1.0 million in administratively allocated legal fees and costs to 3D Medicines. Despite the dispute, 3D Medicines will continue developing and commercializing galinpepimut-S in Greater China, with $191.5 million in potential future milestone payments remaining as of March 31, 2026. Additionally, the company reported an estimated unaudited cash and cash equivalents position of $138.3 million as of June 30, 2026. SELLAS Life Sciences Group, Inc. is a biopharmaceutical company focused on developing therapies for cancer.

SELLAS Life Sciences Group, Inc. amended its executive compensation and severance agreements for CEO Dr. Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic on June 24, 2026. The amendments include lump-sum change-in-control severance benefits for the CEO and enhanced severance packages for the CFO and CDO, including base salary, target bonuses, and COBRA reimbursement. SELLAS Life Sciences Group, Inc. is a biopharmaceutical company focused on developing clinical-stage life sciences products.